List of GLP-1 ini6al approvals since 2005 *products no longer on the market Notable GLP-1 Agonists for Obesity The first GLP-1 drug approved for obesity was Saxenda (liraglutide) from Novo Nordisk, a twice-daily injectable that demonstrated a 7% weight reduction over a year upon its approval
The retail pharmacies segment led the market with a 60% share in 2025 because they offer wide accessibility and convenience for patients seeking prescriptions and ongoing therapy refills
Our findings add to growing evidence that GLP-1 medications may influence more than appetite and blood sugar regulation, said lead author Tadesse Abegaz, PhD, an assistant professor in the School of Pharmacy, University of Texas at El Paso
Some 0.3 mL syringes include half-unit markings (0.5, 1.5, 2.5 units, etc.)
Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products
Different patients, different doctors, different settings